Fennec Pharmaceuticals (FENC) Income towards Parent Company (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Income towards Parent Company data on file, last reported at -$4.7 million in Q4 2025.

• Quarterly Income towards Parent Company fell 276.22% year-over-year to -$4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.7 million (down 2350.82% YoY) and the FY2025 annual result came in at $6.2 million, down 46.91% from the prior year.
• Income towards Parent Company fell to -$4.7 million in Q4 2025, from -$623000.0 in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $12.9 million in Q1 2024 to a low of -$8.0 million in Q3 2022.
• A 5-year average of -$3.3 million and a median of -$4.2 million in 2021 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 316.58% — and 2025, when it tumbled 276.22%.
• Tracing FENC's Income towards Parent Company over 5 years: stood at -$4.3 million in 2021, then plunged by 58.04% to -$6.7 million in 2022, then jumped by 61.08% to -$2.6 million in 2023, then surged by 52.14% to -$1.3 million in 2024, then plunged by 276.22% to -$4.7 million in 2025.
• The last three Income towards Parent Company figures came in at -$4.7 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025), per Business Quant data.